Shaping the future of diabetes care - Roche

More documents

Recommendations

Info

Outlook financials • EBIT impact: – slightly dilutive for the Roche group in 2003 and slightly accretive in 2004 – dilutive for Roche Diagnostics in 2003 and slightly accretive in 2004 Overall, guidance for the Roche Group and Diagnostics unchanged r 22
Public tender offer on Disetronic shares Timing / next steps • Pre-announcement (Voranmeldung) February 10 r • Corporate due diligence February - March • Disetronic Extraordinary shareholder meeting March • Publication of tender offer March 24 • End of first offer period (20 bank days) April 22 • Announce interim results of tender offer End April • Closing May - June 23
Page 1 and 2: Shaping the future of diabetes care
Page 3 and 4: The idea Roche Diagnostics, the wor
Page 5 and 6: Strategic rationale Shaping the fut
Page 7 and 8: Diabetes: a problem of epidemic pro
Page 9 and 10: Glucose monitoring and insulin deli
Page 11 and 12: Roche adding marketing and sales mu
Page 13 and 14: Entry into insulin pump market Grow
Page 15 and 16: Disetronic, the world’s No. 2 in
Page 17 and 18: Business model with two elements br
Page 19 and 20: Proposed transaction structure r Ef
Page 21: Transaction multiples based upon th
Page 25 and 26: About Roche Diabetes Care • Pione
Page 27 and 28: Diabetes is not curable, but it is

Shaping the future of diabetes care - Roche

Create successful ePaper yourself

Delete template?

Save as template?